Literature DB >> 11353062

Pathologic classification of rhabdomyosarcomas and correlations with molecular studies.

D M Parham1.   

Abstract

Rhabdomyosarcoma, the most common soft-tissue malignancy of childhood and adolescence, comprises a group of differing pathobiologic entities linked by their common propensity for formation of neoplastic skeletal muscle, a feature that results from biological forces related to aberrant transcription signals and the resultant production of myogenic proteins. At a molecular level, however, rhabdomyosarcomas form a heterogeneous group that can be subdivided into distinct clinicopathologic entities based on morphologic appearance and genetic makeup. These differing morphologic features were recognized in the mid-1900s by Horn and Enterline with their division of rhabdomyosarcomas into embryonal, alveolar, botryoid, and pleomorphic subtypes. More recent histologic and biologic studies have resulted in description of additional entities, such as spindle cell and anaplastic rhabdomyosarcoma, and refinements in recognition of the original entities, such as solid-alveolar rhabdomyosarcoma. Familiarity with newer classifications and their relationship to molecular aberrations is key to stratifying patients on current therapeutic protocols and proposed innovative genetic therapies.

Entities:  

Mesh:

Year:  2001        PMID: 11353062     DOI: 10.1038/modpathol.3880339

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  50 in total

Review 1.  Rhabdomyosarcoma: current challenges and their implications for developing therapies.

Authors:  Simone Hettmer; Zhizhong Li; Andrew N Billin; Frederic G Barr; D D W Cornelison; Alan R Ehrlich; Denis C Guttridge; Andrea Hayes-Jordan; Lee J Helman; Peter J Houghton; Javed Khan; David M Langenau; Corinne M Linardic; Ranadip Pal; Terence A Partridge; Grace K Pavlath; Rossella Rota; Beat W Schäfer; Janet Shipley; Bruce Stillman; Leonard H Wexler; Amy J Wagers; Charles Keller
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 2.  Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.

Authors:  Brett Hall; Jennifer Dembinski; A Kate Sasser; Matus Studeny; Michael Andreeff; Frank Marini
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

3.  Immunohistochemical detection of myogenin and p21 in methylcholanthrene-induced mouse rhabdomyosarcomas.

Authors:  Makoto Inoue; Haiyan Wu
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

4.  Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.

Authors:  L Krsková; M Mrhalová; D Sumerauer; R Kodet
Journal:  Virchows Arch       Date:  2005-12-20       Impact factor: 4.064

5.  Clinical utility gene card for: Alveolar rhabdomyosarcoma.

Authors:  Zhongxin Yu; Anna Kelsey; Rita Alaggio; David Parham
Journal:  Eur J Hum Genet       Date:  2011-08-10       Impact factor: 4.246

Review 6.  Fibromyxoma of the Jaw: Case Report and Review of the Literature.

Authors:  Thabet Alhousami; Amarpreet Sabharwal; Shivane Gupta; Alfredo Aguirre; Etern Park; Jill M Kramer
Journal:  Head Neck Pathol       Date:  2017-05-16

7.  The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma.

Authors:  Khin Thway; Jayson Wang; Dorte Wren; Melissa Dainton; David Gonzalez; John Swansbury; Cyril Fisher
Journal:  Virchows Arch       Date:  2015-04-26       Impact factor: 4.064

8.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

Review 9.  Applications of neural and mesenchymal stem cells in the treatment of gliomas.

Authors:  Thomas Kosztowski; Hasan A Zaidi; Alfredo Quiñones-Hinojosa
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

Review 10.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.